Bacteromic, a subsidiary of the Warsaw Stock Exchange-listed Scope Fluidics Group, has signed another distribution agreement – this time in Romania – with SC ELTA 90 Medical Research SRL (ELTA MR). The agreement covers the distribution and promotion of the BACTEROMIC system on the Romanian market.
This is the second agreement of this type entered into by a company within the Group in 2026. In early January, a two-year framework distribution agreement was signed with Mefamed, a distributor of medical devices in Turkey.
“Another distribution agreement is a step toward further strengthening the international visibility of the BACTEROMIC system and confirms that foreign distribution partners recognize the value of our solution. The agreements currently being entered into also point to existing market demand for modern solutions in the area of antibiotic susceptibility testing. The distribution agreement in Romania represents another step toward leveraging this potential in cooperation with local partners that maintain relationships with end users,” says Piotr Garstecki, CEO of Scope Fluidics.
ELTA MR is an international company operating, among others, in Romania, Bulgaria, Serbia, and Greece. The company specializes in the supply and distribution of high-quality laboratory equipment, specialized consumables and tests, general laboratory supplies, reagents, and laboratory furniture.
Before distribution activities can commence, ELTA MR will be required to register the BACTEROMIC system in Romania. The procedure should take no longer than one month from the date Bacteromic provides the required documentation, including the IVDR certificate, which Bacteromic expects to obtain in early 2026. The next step will be for the distributor to enter into agreements with end users of the BACTEROMIC system, namely private and public diagnostic laboratories, and to participate in public tender procedures.
It is worth noting that in early January 2026, Scope Fluidics announced it had entered into an agreement covering the distribution of the BACTEROMIC system on the Turkish market. The commencement of distribution will be possible once Mefamed completes registration of the system in accordance with local regulations.